文献速递前列腺癌前列腺增生与排尿功能障碍

丹麦经尿道前列腺电切术后偶发前列腺癌的管理与肿瘤学结局

Management and Oncologic Outcomes of Incidental Prostate Cancer After Transurethral Resection of the Prostate in Denmark.
PubMed 文献 · J Urol · 2024-07-31

该全国性人群观察性研究纳入丹麦2006至2022年接受经尿道前列腺电切术的24494例患者,其中GG1组1016例、GG2组381例。GG1与GG2组15年前列腺癌死亡率分别为8.4%与14%,TURP后活检≥GG2者15年死亡率达30%。作者认为偶发前列腺癌应进一步检查以排除高级别癌。

要点

  • TURP术后偶发前列腺癌GG1组5年进一步MRI或活检累积发生率为36%,GG2组为30%。
  • GG1组15年前列腺癌死亡率为8.4%,GG2组为14%。
  • TURP后活检无癌的GG1患者15年前列腺癌死亡率为0.6%。

核心结论

  • TURP后GG1或GG2前列腺癌患者的前列腺癌死亡率较高,可能因外周带高级别癌未被取样。
  • 偶发前列腺癌患者应进一步检查以排除高级别癌。
  • TURP为GG1者,若后续活检未显示癌,随访应减少至类似于初次良性活检患者的水平。

研究设计与样本

  • 全国性、人群基础的观察性研究,使用丹麦前列腺登记数据库纳入2006至2022年在丹麦接受TURP的患者。
  • 共24494例接受TURP的患者,其中GG1前列腺癌1016例、GG2前列腺癌381例。
  • 采用竞争风险分析估计进一步活检和MRI、治愈性治疗、内分泌治疗及病因特异性死亡率的累积发生率。

主要发现

  • GG1组5年进一步MRI或活检的累积发生率为36%(95% CI 33%-39%),GG2组为30%(95% CI 25%-34%)。
  • GG1组15年前列腺癌死亡率为8.4%(95% CI 5.3%-11%),GG2组为14%(95% CI 7.5%-21%)。
  • GG1组中270例在TURP后接受活检,其中162例(60%)未发现癌;该亚组15年前列腺癌死亡率为0.6%(95% CI 0%-1.8%)。
  • TURP后活检≥GG2者,TURP后15年前列腺癌死亡率为30%(95% CI 9%-50%)。

临床怎么用

  • 原文结论指出偶发前列腺癌患者应进一步检查以排除高级别癌。
  • 原文结论指出TURP为GG1者,一旦后续活检未显示癌,随访应减少至类似于初次良性活检患者的水平。

局限性

  • 主要局限性为随访异质性,与更标准化的随访相比,可能导致前列腺癌死亡率被高估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Approximately 1 in 10 patients without prior prostate biopsy undergoing surgery for lower urinary tract symptoms harbors incidental prostate cancer; however, practice guidelines do not provide recommendations for its management. We aimed at describing the oncologic outcomes of patients with Grade Group (GG) 1 and GG2 prostate cancer diagnosed at transurethral resection of the prostate (TURP). MATERIALS AND METHODS: This was a nationwide, population-based, observational study of patients undergoing TURP in Denmark from 2006 to 2022 using the Danish Prostate Registry. We estimated the cumulative incidence of further biopsies and MRI, curative treatment, endocrine treatment, and cause-specific mortality with competing risk analyses. RESULTS: Among 24,494 patients who underwent TURP, there were 1016 men with GG1 and 381 with GG2 prostate cancer. The 5-year cumulative incidence of further MRIs or biopsies was 36% (95% CI 33%-39%) for GG1 and 30% (95% CI 25%-34%) for GG2 disease. Fifteen-year prostate cancer mortality was 8.4% (95% CI 5.3%-11%) for GG1 and 14% (7.5%-21%) for GG2. A total of 270 men with GG1 disease underwent a biopsy after the TURP, and 162 (60%) had no cancer; in this group, prostate cancer mortality after 15 years was 0.6% (95% CI 0%-1.8%). Men with post-TURP biopsy ≥ GG2 had a prostate cancer mortality of 30% (95% CI 9%-50%) 15 years post TURP. The major limitation was the heterogeneous follow-up, which could lead to an overestimation of prostate cancer mortality compared to a more standardized follow-up. CONCLUSIONS: We observed high prostate cancer mortality after TURP with GG1 or GG2, likely due to unsampled high-grade cancer in the peripheral zone. Patients with incidental prostate cancer should be further investigated to rule out high-grade cancer. For patients with GG1 on TURP, once a subsequent biopsy does not show cancer, follow-up should be lessened similar to that of patients with an initial nonmalignant biopsy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Leni R, Vickers AJ, Brasso K, et al. Management and Oncologic Outcomes of Incidental Prostate Cancer After Transurethral Resection of the Prostate in Denmark. J Urol. 2024. PMID: 39083481. doi:10.1097/JU.0000000000004159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。